BMK delivered a 9% reported increase in sales in H1’18 despite FX headwinds (up 17% at constant exchange rates) to £75.7m, together with a 91% increase in adjusted EBITDA. This was driven by strong performance in Genetics and Advanced Nutrition and a higher margin product mix in these divisions. The results were accompanied by a confident message that the growth strategy is delivering, with FY18 forecasts on track.
26 Jun 2018
Delivering on strategic and financial targets
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Delivering on strategic and financial targets
Benchmark Holdings Plc (BMK:LON) | 0 0 0.6% | Mkt Cap: 319.9m
- Published:
26 Jun 2018 -
Author:
Emma Ulker -
Pages:
9
BMK delivered a 9% reported increase in sales in H1’18 despite FX headwinds (up 17% at constant exchange rates) to £75.7m, together with a 91% increase in adjusted EBITDA. This was driven by strong performance in Genetics and Advanced Nutrition and a higher margin product mix in these divisions. The results were accompanied by a confident message that the growth strategy is delivering, with FY18 forecasts on track.